summary of financial results worldwide revenues in 2016 of $ 12.483 billion increased 21.4 % from the prior year , compared with an increase of 21.7 % in 2015 . revenue growth in 2016 largely reflected the impact from the inclusion of carefusion 's sales in the company 's results for a full fiscal year in 2016 as compared with only half the fiscal year in 2015 , as discussed above . revenues in 2016 also reflected volume growth of approximately 4.2 % , which included an unfavorable impact from the termination of a distribution agreement in the respiratory solutions unit . revenue growth in 2016 additionally reflected an unfavorable foreign currency translation impact of approximately 3.1 % and a relatively immaterial favorable impact from price . revenue growth in 2015 reflected a 24.1 % impact from the inclusion of carefusion 's sales in the company 's results from april 1 , 2015 , as discussed above , as well as volume growth of 5.1 % and unfavorable foreign currency translation of 7.5 % . volume growth in 2016 reflected the following : medical segment volume growth was driven by the medication and procedural solutions unit 's international sales of safety-engineered products , the diabetes care unit 's sales of pen needles and the pharmaceutical systems unit 's sales of self-injection systems . fiscal year 2016 revenues in the respiratory solutions unit were unfavorably impacted by the termination of a distribution contract , as noted above . life sciences segment volume growth was driven by the preanalytical systems unit 's global sales of safety-engineered products , the diagnostic systems unit 's sales of automated platforms and the biosciences unit 's u.s. sales of research instrument and reagent sales . the biosciences unit 's international fiscal year 2016 revenues were unfavorably impacted by pressure on sales of hiv-related clinical products in africa . u.s. medical segment volume growth in 2016 primarily reflected the sales of infusion disposables and self-injection systems . u.s. life sciences segment volume growth in 2016 was driven by sales of safety-engineered products , microbiology platforms , molecular diagnostic platforms , and research reagents , as well as by research instrument placements . the medical segment 's international volume growth in 2016 was driven by sales of safety-engineered and flush products . the life sciences segment 's international volume growth in 2016 was driven by sales of safety-engineered products , microbiology and women 's health and cancer platforms , but was negatively impacted by pressure on hiv-related clinical products in africa , as noted above . worldwide sales of safety-engineered products reflected volume growth that was attributable to both segments . fiscal year 2016 sales in the united states of safety-engineered devices of $ 1.805 billion increased 22.8 % and fiscal year 2016 international sales of safety-engineered devices of $ 1.231 billion grew 9.3 % over the prior year 's period , inclusive of an estimated 7.5 % unfavorable impact due to foreign currency translation . we continue to invest in research and development , geographic expansion , and new product promotions to drive further revenue and profit growth . our ability to sustain our long-term growth will depend on a number of factors , including our ability to expand our core business ( including geographical expansion ) , develop innovative new products , and continue to improve operating efficiency and organizational effectiveness . while the economic environment for the healthcare industry has stabilized , pricing pressures continue for some of our products . healthcare utilization has stabilized and slightly improved in the united states ; however , any destabilization in the future could adversely impact our u.s. businesses . additionally , macroeconomic challenges in europe continue to constrain healthcare utilization , although we currently view the environment as stable . in emerging markets , the company 's growth is dependent primarily on government funding for healthcare systems . 16 our financial position remains strong , with cash flows from operating activities totaling $ 2.559 billion in 2016 . at september 30 , 2016 , we had $ 1.6 billion in cash and equivalents and short-term investments . we continued to return value to our shareholders in the form of dividends . during fiscal year 2016 , we paid cash dividends of $ 562 million . no shares were repurchased during fiscal year 2016 . each reporting period , we face currency exposure that arises from translating the results of our worldwide operations to the u.s. dollar at exchange rates that fluctuate from the beginning of such period . the ongoing relative strength of the u.s. dollar resulted in an unfavorable foreign currency translation impact to our revenue growth during the fiscal year . we evaluate our results of operations on both a reported and a foreign currency-neutral basis , which excludes the impact of fluctuations in foreign currency exchange rates . as exchange rates are an important factor in understanding period-to-period comparisons , we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors ' ability to understand our operating results and evaluate our performance in comparison to prior periods . foreign currency-neutral ( `` fxn `` ) information compares results between periods as if exchange rates had remained constant period-over-period . we use results on a foreign currency-neutral basis as one measure to evaluate our performance . we calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results . these results should be considered in addition to , not as a substitute for , results reported in accordance with u.s. generally accepted accounting principles ( `` gaap `` ) . results on a foreign currency-neutral basis , as we present them , may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with u.s. gaap . story_separator_special_tag income taxes the income tax rates in 2016 , 2015 and 2014 were as follows : replace_table_token_14_th the increase in the effective income tax rate from 2015 to 2016 is primarily due to the decrease in tax benefits on specified items . the tax benefits of the specified items shown earlier reduced the income tax rates in 2016 and 2015 by 1,090 and 1,720 basis points , respectively , as the tax benefits on these specified items were primarily incurred in higher tax jurisdictions . the income tax rates in fiscal years 2016 and 2015 also reflected the extension of the u.s. research and development income tax credit , which was partially offset by the unfavorable impact of one-time discrete items . the effective income tax rate in 2014 reflected our decision to change our position of permanent reinvestment with respect to the unremitted earnings of brazil and certain other latin american jurisdictions , the impact of which was more than offset by the benefits resulting from discrete one-time items and geographic mix . net income and diluted earnings per share net income and diluted earnings per share in 2016 , 2015 and 2014 were as follows : replace_table_token_15_th 22 financial instrument market risk we selectively use financial instruments to manage market risk , primarily foreign currency exchange risk and interest rate risk relating to our ongoing business operations . the counterparties to these contracts are highly rated financial institutions . we do not enter into financial instruments for trading or speculative purposes . foreign exchange risk bd and its subsidiaries transact business in various foreign currencies throughout europe , greater asia , canada and latin america . we face foreign currency exposure from the effect of fluctuating exchange rates on payables and receivables relating to transactions that are denominated in currencies other than our functional currency . these payables and receivables primarily arise from intercompany transactions . we hedge substantially all such exposures , primarily through the use of forward contracts . we also face currency exposure that arises from translating the results of our worldwide operations , including sales , to the u.s. dollar at exchange rates that have fluctuated from the beginning of a reporting period . from time to time , we may purchase forward contracts and options to hedge certain forecasted transactions that are denominated in foreign currencies in order to partially protect against a reduction in the value of future earnings resulting from adverse foreign exchange rate movements . gains or losses on derivative instruments are largely offset by the gains or losses on the underlying hedged transactions . we did not enter into contracts to hedge cash flows against foreign currency fluctuations in fiscal year 2016 or 2015 . derivative financial instruments are recorded on our balance sheet at fair value . for foreign currency derivatives , market risk is determined by calculating the impact on fair value of an assumed change in foreign exchange rates relative to the u.s. dollar . fair values were estimated based upon observable inputs , specifically spot currency rates and foreign currency prices for similar assets and liabilities . with respect to the foreign currency derivative instruments outstanding at september 30 , 2016 and 2015 , the impact changes in the u.s. dollar would have on pre-tax earnings was estimated as follows : replace_table_token_16_th these calculations do not reflect the impact of exchange gains or losses on the underlying transactions that would substantially offset the results of the derivative instruments . interest rate risk our primary interest rate risk relates to u.s. dollar borrowings which are partially offset by u.s. dollar cash investments . when managing interest rate exposures , we strive to achieve an appropriate balance between fixed and floating rate instruments . we may enter into interest rate swaps to help maintain this balance and manage debt and interest-bearing investments in tandem , since these items have an offsetting impact on interest rate exposure . for interest rate derivative instruments , fair values are measured based upon the present value of expected future cash flows using market-based observable inputs including credit risk and interest rate yield curves . market risk for these instruments is determined by calculating the impact to fair value of an assumed change in interest rates across all maturities . with respect to the interest rate derivatives outstanding at september 30 , 2016 and 2015 , the impact changes in the interest rate would have on the fair value of these derivatives was estimated as follows : replace_table_token_17_th based on our overall interest rate exposure at september 30 , 2016 and 2015 , a 10 % change in interest rates would not have a material effect on our earnings or cash flows over a one-year period . 23 liquidity and capital resources the following table summarizes our consolidated statement of cash flows in 2016 , 2015 and 2014 : replace_table_token_18_th net cash flows from operating activities the fiscal year 2016 , 2015 and 2014 changes in net cash provided by operating activities was primarily attributable to net income , as adjusted for depreciation and amortization and other non-cash items . the fiscal year 2016 change in operating assets and liabilities was a net source of cash and primarily reflected higher levels of accounts payable and accrued expenses as well as lower levels of inventory , prepayments and financing receivables , partially offset by higher levels of accounts receivables . the fiscal year 2015 change in operating assets and liabilities was a net source of cash and primarily reflected lower levels of inventory and higher levels of accounts payable and accrued expenses , partially offset by higher levels of prepayments . the lower levels of inventory reflected the impact , primarily recognized in the third quarter of fiscal year 2015 , of the acquisition fair value step-up adjustment recorded relative to carefusion 's inventory on the acquisition date . net cash provided by operating activities in 2016 was reduced by changes in the

net cash flows from investing activities capital expenditures our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities , and support our strategy of geographic expansion with select investments in growing markets . capital expenditures of $ 693 million , $ 596 million , $ 592 million in 2016 , 2015 and 2014 , respectively , primarily related to manufacturing capacity expansions and details of spending by segment are contained in note 6 to the consolidated financial statements contained in item 8. financial statements and supplementary data . investments cash inflows from the sales of investments of $ 840 million in 2015 were attributable to the maturities of time deposits in europe , latin america and asia pacific . acquisitions of businesses cash outflows relating to acquisitions in 2015 and 2014 were $ 8.4 billion and $ 40 million , respectively . cash outflows relating to acquisitions in 2015 were primarily attributable to the completion of the carefusion acquisition in the second quarter of fiscal year 2015 . cash outflows relating to acquisitions in 2014 represented cash paid to acquire alverix , inc. in the second quarter of fiscal year 2014 . for further discussion , refer to note 9 to the consolidated financial statements contained in item 8. financial statements and supplementary data . net cash flows from financing activities net cash used for financing activities in 2016 included a net $ 500 million reduction of our commercial paper program balance and the third quarter repayment of $ 750 million of floating rate notes due on june 15 , 2016. net cash provided by financing activities in 2015 included the proceeds , which were used to finance our acquisition of carefusion , from $ 6.2 billion of notes issued in december 2014 and $ 500 million total proceeds from net borrowings under commercial paper programs .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash flows from investing activities capital expenditures our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities , and support our strategy of geographic expansion with select investments in growing markets . capital expenditures of $ 693 million , $ 596 million , $ 592 million in 2016 , 2015 and 2014 , respectively , primarily related to manufacturing capacity expansions and details of spending by segment are contained in note 6 to the consolidated financial statements contained in item 8. financial statements and supplementary data . investments cash inflows from the sales of investments of $ 840 million in 2015 were attributable to the maturities of time deposits in europe , latin america and asia pacific . acquisitions of businesses cash outflows relating to acquisitions in 2015 and 2014 were $ 8.4 billion and $ 40 million , respectively . cash outflows relating to acquisitions in 2015 were primarily attributable to the completion of the carefusion acquisition in the second quarter of fiscal year 2015 . cash outflows relating to acquisitions in 2014 represented cash paid to acquire alverix , inc. in the second quarter of fiscal year 2014 . for further discussion , refer to note 9 to the consolidated financial statements contained in item 8. financial statements and supplementary data . net cash flows from financing activities net cash used for financing activities in 2016 included a net $ 500 million reduction of our commercial paper program balance and the third quarter repayment of $ 750 million of floating rate notes due on june 15 , 2016. net cash provided by financing activities in 2015 included the proceeds , which were used to finance our acquisition of carefusion , from $ 6.2 billion of notes issued in december 2014 and $ 500 million total proceeds from net borrowings under commercial paper programs .
```    
 Suspicious Activity Report : summary of financial results worldwide revenues in 2016 of $ 12.483 billion increased 21.4 % from the prior year , compared with an increase of 21.7 % in 2015 . revenue growth in 2016 largely reflected the impact from the inclusion of carefusion 's sales in the company 's results for a full fiscal year in 2016 as compared with only half the fiscal year in 2015 , as discussed above . revenues in 2016 also reflected volume growth of approximately 4.2 % , which included an unfavorable impact from the termination of a distribution agreement in the respiratory solutions unit . revenue growth in 2016 additionally reflected an unfavorable foreign currency translation impact of approximately 3.1 % and a relatively immaterial favorable impact from price . revenue growth in 2015 reflected a 24.1 % impact from the inclusion of carefusion 's sales in the company 's results from april 1 , 2015 , as discussed above , as well as volume growth of 5.1 % and unfavorable foreign currency translation of 7.5 % . volume growth in 2016 reflected the following : medical segment volume growth was driven by the medication and procedural solutions unit 's international sales of safety-engineered products , the diabetes care unit 's sales of pen needles and the pharmaceutical systems unit 's sales of self-injection systems . fiscal year 2016 revenues in the respiratory solutions unit were unfavorably impacted by the termination of a distribution contract , as noted above . life sciences segment volume growth was driven by the preanalytical systems unit 's global sales of safety-engineered products , the diagnostic systems unit 's sales of automated platforms and the biosciences unit 's u.s. sales of research instrument and reagent sales . the biosciences unit 's international fiscal year 2016 revenues were unfavorably impacted by pressure on sales of hiv-related clinical products in africa . u.s. medical segment volume growth in 2016 primarily reflected the sales of infusion disposables and self-injection systems . u.s. life sciences segment volume growth in 2016 was driven by sales of safety-engineered products , microbiology platforms , molecular diagnostic platforms , and research reagents , as well as by research instrument placements . the medical segment 's international volume growth in 2016 was driven by sales of safety-engineered and flush products . the life sciences segment 's international volume growth in 2016 was driven by sales of safety-engineered products , microbiology and women 's health and cancer platforms , but was negatively impacted by pressure on hiv-related clinical products in africa , as noted above . worldwide sales of safety-engineered products reflected volume growth that was attributable to both segments . fiscal year 2016 sales in the united states of safety-engineered devices of $ 1.805 billion increased 22.8 % and fiscal year 2016 international sales of safety-engineered devices of $ 1.231 billion grew 9.3 % over the prior year 's period , inclusive of an estimated 7.5 % unfavorable impact due to foreign currency translation . we continue to invest in research and development , geographic expansion , and new product promotions to drive further revenue and profit growth . our ability to sustain our long-term growth will depend on a number of factors , including our ability to expand our core business ( including geographical expansion ) , develop innovative new products , and continue to improve operating efficiency and organizational effectiveness . while the economic environment for the healthcare industry has stabilized , pricing pressures continue for some of our products . healthcare utilization has stabilized and slightly improved in the united states ; however , any destabilization in the future could adversely impact our u.s. businesses . additionally , macroeconomic challenges in europe continue to constrain healthcare utilization , although we currently view the environment as stable . in emerging markets , the company 's growth is dependent primarily on government funding for healthcare systems . 16 our financial position remains strong , with cash flows from operating activities totaling $ 2.559 billion in 2016 . at september 30 , 2016 , we had $ 1.6 billion in cash and equivalents and short-term investments . we continued to return value to our shareholders in the form of dividends . during fiscal year 2016 , we paid cash dividends of $ 562 million . no shares were repurchased during fiscal year 2016 . each reporting period , we face currency exposure that arises from translating the results of our worldwide operations to the u.s. dollar at exchange rates that fluctuate from the beginning of such period . the ongoing relative strength of the u.s. dollar resulted in an unfavorable foreign currency translation impact to our revenue growth during the fiscal year . we evaluate our results of operations on both a reported and a foreign currency-neutral basis , which excludes the impact of fluctuations in foreign currency exchange rates . as exchange rates are an important factor in understanding period-to-period comparisons , we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors ' ability to understand our operating results and evaluate our performance in comparison to prior periods . foreign currency-neutral ( `` fxn `` ) information compares results between periods as if exchange rates had remained constant period-over-period . we use results on a foreign currency-neutral basis as one measure to evaluate our performance . we calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results . these results should be considered in addition to , not as a substitute for , results reported in accordance with u.s. generally accepted accounting principles ( `` gaap `` ) . results on a foreign currency-neutral basis , as we present them , may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with u.s. gaap . story_separator_special_tag income taxes the income tax rates in 2016 , 2015 and 2014 were as follows : replace_table_token_14_th the increase in the effective income tax rate from 2015 to 2016 is primarily due to the decrease in tax benefits on specified items . the tax benefits of the specified items shown earlier reduced the income tax rates in 2016 and 2015 by 1,090 and 1,720 basis points , respectively , as the tax benefits on these specified items were primarily incurred in higher tax jurisdictions . the income tax rates in fiscal years 2016 and 2015 also reflected the extension of the u.s. research and development income tax credit , which was partially offset by the unfavorable impact of one-time discrete items . the effective income tax rate in 2014 reflected our decision to change our position of permanent reinvestment with respect to the unremitted earnings of brazil and certain other latin american jurisdictions , the impact of which was more than offset by the benefits resulting from discrete one-time items and geographic mix . net income and diluted earnings per share net income and diluted earnings per share in 2016 , 2015 and 2014 were as follows : replace_table_token_15_th 22 financial instrument market risk we selectively use financial instruments to manage market risk , primarily foreign currency exchange risk and interest rate risk relating to our ongoing business operations . the counterparties to these contracts are highly rated financial institutions . we do not enter into financial instruments for trading or speculative purposes . foreign exchange risk bd and its subsidiaries transact business in various foreign currencies throughout europe , greater asia , canada and latin america . we face foreign currency exposure from the effect of fluctuating exchange rates on payables and receivables relating to transactions that are denominated in currencies other than our functional currency . these payables and receivables primarily arise from intercompany transactions . we hedge substantially all such exposures , primarily through the use of forward contracts . we also face currency exposure that arises from translating the results of our worldwide operations , including sales , to the u.s. dollar at exchange rates that have fluctuated from the beginning of a reporting period . from time to time , we may purchase forward contracts and options to hedge certain forecasted transactions that are denominated in foreign currencies in order to partially protect against a reduction in the value of future earnings resulting from adverse foreign exchange rate movements . gains or losses on derivative instruments are largely offset by the gains or losses on the underlying hedged transactions . we did not enter into contracts to hedge cash flows against foreign currency fluctuations in fiscal year 2016 or 2015 . derivative financial instruments are recorded on our balance sheet at fair value . for foreign currency derivatives , market risk is determined by calculating the impact on fair value of an assumed change in foreign exchange rates relative to the u.s. dollar . fair values were estimated based upon observable inputs , specifically spot currency rates and foreign currency prices for similar assets and liabilities . with respect to the foreign currency derivative instruments outstanding at september 30 , 2016 and 2015 , the impact changes in the u.s. dollar would have on pre-tax earnings was estimated as follows : replace_table_token_16_th these calculations do not reflect the impact of exchange gains or losses on the underlying transactions that would substantially offset the results of the derivative instruments . interest rate risk our primary interest rate risk relates to u.s. dollar borrowings which are partially offset by u.s. dollar cash investments . when managing interest rate exposures , we strive to achieve an appropriate balance between fixed and floating rate instruments . we may enter into interest rate swaps to help maintain this balance and manage debt and interest-bearing investments in tandem , since these items have an offsetting impact on interest rate exposure . for interest rate derivative instruments , fair values are measured based upon the present value of expected future cash flows using market-based observable inputs including credit risk and interest rate yield curves . market risk for these instruments is determined by calculating the impact to fair value of an assumed change in interest rates across all maturities . with respect to the interest rate derivatives outstanding at september 30 , 2016 and 2015 , the impact changes in the interest rate would have on the fair value of these derivatives was estimated as follows : replace_table_token_17_th based on our overall interest rate exposure at september 30 , 2016 and 2015 , a 10 % change in interest rates would not have a material effect on our earnings or cash flows over a one-year period . 23 liquidity and capital resources the following table summarizes our consolidated statement of cash flows in 2016 , 2015 and 2014 : replace_table_token_18_th net cash flows from operating activities the fiscal year 2016 , 2015 and 2014 changes in net cash provided by operating activities was primarily attributable to net income , as adjusted for depreciation and amortization and other non-cash items . the fiscal year 2016 change in operating assets and liabilities was a net source of cash and primarily reflected higher levels of accounts payable and accrued expenses as well as lower levels of inventory , prepayments and financing receivables , partially offset by higher levels of accounts receivables . the fiscal year 2015 change in operating assets and liabilities was a net source of cash and primarily reflected lower levels of inventory and higher levels of accounts payable and accrued expenses , partially offset by higher levels of prepayments . the lower levels of inventory reflected the impact , primarily recognized in the third quarter of fiscal year 2015 , of the acquisition fair value step-up adjustment recorded relative to carefusion 's inventory on the acquisition date . net cash provided by operating activities in 2016 was reduced by changes in the

